GSK’s Zejula secures EC approval to treat advanced ovarian cancer
GSK said that Zejula is the first monotherapy for patients with platinum-responsive advanced ovarian cancer in the European…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
30 Oct 20
GSK said that Zejula is the first monotherapy for patients with platinum-responsive advanced ovarian cancer in the European…
28 Oct 20
Pfizer’s regulatory filing for abrocitinib is based on clinical trial data showing improvement in symptoms, along with a…
23 Oct 20
Veklury becomes the first and only FDA approved treatment for Covid-19 in the US, which helps recovery of…
21 Oct 20
The FDA has granted the Prescription Drug User Fee Act (PDUFA) date to announce its regulatory decision, during…
20 Oct 20
Phase 3 CheckMate-9ER trial showed that Opdivo plus Cabometyx improved overall survival, progression-free survival and objective response rate
19 Oct 20
The US regulator approved Genentech’s Supplemental New Drug Applications for Venclexta plus azacitidine under its RTOR and Project…
15 Oct 20
Inmazeb comprises three monoclonal antibodies of similar structure, including atoltivimab, maftivimab and odesivimab-ebgn
12 Oct 20
C3G is a rare and severe primary glomerulonephritis, prevalent in adolescents and young adults, characterised by complement dysregulation
05 Oct 20
The US regulatory agency granted the breakthrough status for Farxiga based on the positive clinical evidence from the…
05 Oct 20
The FDA approval is based on the Phase 3 CheckMate -743 trial, which evaluated Opdivo plus Yervoy compared…